REGN vs. VRTX: Regeneron Pharmaceuticals vs. Vertex Pharmaceuticals Stock Comparison
How do Regeneron Pharmaceuticals (REGN) and Vertex Pharmaceuticals (VRTX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Regeneron Pharmaceuticals (REGN) and Vertex Pharmaceuticals (VRTX) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | REGN | VRTX |
|---|---|---|
| Name | Regeneron Pharmaceuticals, Inc. | Vertex Pharmaceuticals Incorporated Common Stock |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 93.55 billion USD | 138.71 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | April 2, 1991 | July 24, 1991 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | REGN | VRTX |
|---|---|---|
| Total Return (1Y) | 40.87% | 34.89% |
| Total Return (3Y, Annualized) | 5.15% | 14.44% |
| Total Return (5Y, Annualized) | 8.58% | 23.65% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | REGN | VRTX |
|---|---|---|
| Volatility (1Y, Annualized) | 34.08% | 29.73% |
| Beta (5Y) | 0.10 | 0.29 |
| Max Drawdown (5Y) | -59.69% | -29.07% |
| Avg. Volume (3M) | 772.95K | 1.25M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | REGN | VRTX |
|---|---|---|
| Sharpe Ratio (1Y) | 1.07 | 1.03 |
| Sortino Ratio (1Y) | 1.70 | 1.68 |
Profitability
ROE (TTM)
Both Regeneron Pharmaceuticals (REGN) at 14.95% and Vertex Pharmaceuticals (VRTX) at 20.80% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.95%
- Max
- 109.18%
- REGN
- 14.95%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.80%
- Max
- 109.18%
- VRTX
- 20.80%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Regeneron Pharmaceuticals (REGN) at 28.51% and Vertex Pharmaceuticals (VRTX) at 30.70% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
28.51%
- REGN
- 28.51%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.70%
- VRTX
- 30.70%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Regeneron Pharmaceuticals (REGN) at 40.46% and Vertex Pharmaceuticals (VRTX) at 35.57% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
40.46%
- Max
- 83.12%
- REGN
- 40.46%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
35.57%
- Max
- 83.12%
- VRTX
- 35.57%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | REGN | VRTX |
|---|---|---|
| ROE (TTM) | 14.95% | 20.80% |
| ROA (TTM) | 7.59% | 10.62% |
| Net Margin (TTM) | 28.51% | 30.70% |
| Operating Margin (TTM) | 40.46% | 35.57% |
| Gross Margin (TTM) | 46.73% | 54.81% |
Growth
Revenue Growth
Both Regeneron Pharmaceuticals (REGN) at 0.99% and Vertex Pharmaceuticals (VRTX) at 8.90% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: Regeneron Pharmaceuticals (REGN) reports EPS growth of 8.19%, ranked against its industry; Vertex Pharmaceuticals (VRTX) has no EPS growth figure this period.
Growth Metrics
| Metric | REGN | VRTX |
|---|---|---|
| Revenue Growth (YoY) | 0.99% | 8.90% |
| Revenue Growth (3Y CAGR) | 5.62% | 10.35% |
| EPS Growth (YoY) | 8.19% | -- |
| EPS Growth (3Y CAGR) | 2.77% | 6.12% |
Financial Strength
Current Ratio (MRQ)
Regeneron Pharmaceuticals (REGN) at 3.35 keeps current ratio within its industry’s typical mid-range, while Vertex Pharmaceuticals (VRTX) at 2.34 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for VRTX.
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.35
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- REGN
- 3.35
- Q1
- 2.47
- Min
- 0.10
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.34
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- VRTX
- 2.34
- Min
- 0.10
Debt / Equity (MRQ)
Both Regeneron Pharmaceuticals (REGN) at 0.08 and Vertex Pharmaceuticals (VRTX) at 0.31 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.08
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- REGN
- 0.08
- Q1
- 0.02
- Min
- 0.00
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.31
- Max
- 1.42
- Q3
- 0.65
- VRTX
- 0.31
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | REGN | VRTX |
|---|---|---|
| Current Ratio (MRQ) | 3.35 | 2.34 |
| Debt / Equity (MRQ) | 0.08 | 0.31 |
| Net Debt / EBITDA | -1.17 | 0.03 |
Dividends
Dividend Yield (TTM)
Vertex Pharmaceuticals (VRTX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Regeneron Pharmaceuticals (REGN) reports a yield of 0.41%, ranking against industry peers normally.
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.41%
- REGN
- 0.41%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- VRTX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Vertex Pharmaceuticals (VRTX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Regeneron Pharmaceuticals (REGN) reports a payout of 8.18%, ranking against industry peers normally.
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.18%
- REGN
- 8.18%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- VRTX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | REGN | VRTX |
|---|---|---|
| Dividend Yield (TTM) | 0.41% | 0.00% |
| Dividend Payout Ratio (TTM) | 8.18% | 0.00% |
Valuation
P/E Ratio (TTM)
Both Regeneron Pharmaceuticals (REGN) at 19.99 and Vertex Pharmaceuticals (VRTX) at 35.21 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.99
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- REGN
- 19.99
- Q1
- 13.30
- Min
- 0.07
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
35.21
- Max
- 85.34
- Q3
- 43.46
- VRTX
- 35.21
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Regeneron Pharmaceuticals (REGN) at 5.54 and Vertex Pharmaceuticals (VRTX) at 10.71 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.54
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- REGN
- 5.54
- Q1
- 3.01
- Min
- 0.01
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.71
- Max
- 58.18
- Q3
- 25.77
- VRTX
- 10.71
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Regeneron Pharmaceuticals (REGN) at 2.71 is valued about in line with its industry on P/B ratio, while Vertex Pharmaceuticals (VRTX) at 6.63 carries an above-peer premium to book — VRTX is pricier on assets.
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.71
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- REGN
- 2.71
- Q1
- 1.69
- Min
- -5.59
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.63
- Max
- 13.53
- VRTX
- 6.63
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | REGN | VRTX |
|---|---|---|
| P/E Ratio (TTM) | 19.99 | 35.21 |
| P/S Ratio (TTM) | 5.54 | 10.71 |
| P/B Ratio (MRQ) | 2.71 | 6.63 |
| Free Cash Flow Yield (TTM) | 2.76% | 1.69% |